Cullinan Therapeutics, Inc. (CGEM)
15.51
+0.98
(+6.74%)
USD |
NASDAQ |
Oct 02, 16:00
15.50
-0.01
(-0.06%)
After-Hours: 06:58
Cullinan Therapeutics Max Drawdown (5Y) : 89.24% for Sept. 30, 2026
Max Drawdown (5Y) Chart
Historical Max Drawdown (5Y) Data
| Date | Value |
|---|---|
| September 30, 2026 | 89.24% |
| August 31, 2026 | 89.24% |
| July 31, 2026 | 89.24% |
| June 30, 2026 | 89.24% |
| May 31, 2026 | 89.24% |
| April 30, 2026 | 89.24% |
| March 31, 2026 | 89.24% |
| February 28, 2026 | 89.24% |
| January 31, 2026 | 89.24% |
| December 31, 2025 | 89.24% |
| November 30, 2025 | 89.24% |
| October 31, 2025 | 89.24% |
| September 30, 2025 | 88.90% |
| August 31, 2025 | 86.84% |
| July 31, 2025 | 86.65% |
| June 30, 2025 | 86.65% |
| May 31, 2025 | 86.65% |
| April 30, 2025 | 86.43% |
| March 31, 2025 | 86.32% |
| February 28, 2025 | 86.32% |
| January 31, 2025 | 86.32% |
| December 31, 2024 | 86.32% |
| November 30, 2024 | 86.32% |
| October 31, 2024 | 86.32% |
| September 30, 2024 | 86.32% |
| Date | Value |
|---|---|
| August 31, 2024 | 86.32% |
| July 31, 2024 | 86.32% |
| June 30, 2024 | 86.32% |
| May 31, 2024 | 86.32% |
| April 30, 2024 | 86.32% |
| March 31, 2024 | 86.32% |
| February 29, 2024 | 86.32% |
| January 31, 2024 | 86.32% |
| December 31, 2023 | 86.32% |
| November 30, 2023 | 86.32% |
| October 31, 2023 | 86.32% |
| September 30, 2023 | 86.32% |
| August 31, 2023 | 86.32% |
| July 31, 2023 | 86.32% |
| June 30, 2023 | 86.32% |
| May 31, 2023 | 86.32% |
| April 30, 2023 | 86.32% |
| March 31, 2023 | 86.32% |
| February 28, 2023 | 86.32% |
| January 31, 2023 | 86.32% |
| December 31, 2022 | 86.32% |
| November 30, 2022 | 86.32% |
| October 31, 2022 | 86.32% |
| September 30, 2022 | 86.32% |
| August 31, 2022 | 86.32% |
Max Drawdown Definition
Max drawdown is an indicator of the risk of a portfolio chosen based on a certain strategy. It measures the largest single drop from peak to bottom in the value of a portfolio before a new peak is achieved.
Max Drawdown (5Y) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Max Drawdown (5Y) Benchmarks
| Climb Bio, Inc. | 96.05% |
| MapLight Therapeutics, Inc. | -- |
| Arrowhead Pharmaceuticals, Inc. | 88.96% |
| Oncolytics Biotech, Inc. | 92.83% |
| Sangamo Therapeutics, Inc. | 99.68% |
Max Drawdown (5Y) Related Metrics
| Alpha (5Y) | -10.74 |
| Beta (5Y) | -0.0469 |
| Annualized Standard Deviation of Monthly Returns (5Y Lookback) | 65.35% |
| Historical Sharpe Ratio (5Y) | -0.1715 |
| Historical Sortino (5Y) | -0.4287 |
| Monthly Value at Risk (VaR) 5% (5Y Lookback) | 22.77% |